Table 1.
Patient Characteristics
| Characteristic | Sequence AMPH EROS/Placebo (n = 9) | Sequence Placebo/AMPH EROS (n = 9) | Total (n = 18) |
|---|---|---|---|
| Sex, n (%) | |||
| Male | 7 (77.8) | 7 (77.8) | 14 (77.8) |
| Female | 2 (22.2) | 2 (22.2) | 4 (22.2) |
| Age, years | |||
| Mean (SD) | 8.8 (2.05) | 9.2 (1.39) | 9.0 (1.71) |
| Median | 10.0 | 10.0 | 10.0 |
| Range (min, max) | 6, 11 | 6, 10 | 6, 11 |
| Race, n (%) | |||
| White | 8 (88.9) | 8 (88.9) | 16 (88.9) |
| Black | 1 (11.1) | 1 (11.1) | 2 (11.1) |
| Othera | 0 | 0 | 0 |
| Ethnicity, n (%) | |||
| Hispanic/Latino | 1 (11.1) | 4 (44.4) | 5 (27.8) |
| Non-Hispanic/Latino | 8 (88.9) | 5 (55.6) | 13 (72.2) |
| ADHD type, n (%) | |||
| Predominantly inattentive | 2 (22.2) | 1 (11.1) | 3 (16.7) |
| Predominantly hyperactive/impulsive | 0 | 0 | 0 |
| Combined | 7 (77.8) | 8 (88.9) | 15 (83.3) |
Intent-to-treat population.
a
Race designation of “other” includes Asian, Native Hawaiian, and biracial.
ADHD, attention-deficit/hyperactivity disorder; AMPH EROS, amphetamine extended-release oral suspension; SD, standard deviation; SE, standard error.